CLEVELAND, Sept. 21, 2017 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the company's MRIdian and
MRIdian Linac systems will be featured at the Annual Meeting of the
American Society for Radiation Oncology (ASTRO), with a number of
presentations highlighting clinical experience and patient
outcomes. The ASTRO meeting will be held September 24-27, 2017 in San Diego.
MR-guided radiation therapy remains a significant area of
interest, as reflected by the 21 MRIdian clinical presentations and
posters accepted as part of ASTRO's Scientific Sessions. These
presentations will be given by MRIdian users from around the world
including National Cancer Center (NCC) in Tokyo, Japan; Seoul National University Hospital (SNUH) in Seoul, South Korea; Policlinico Agostino
Gemelli, Universita Cattolica del Sacro Cuore, Gemelli ART in
Rome, Italy; University of California, Los Angeles Health System
and Jonsson Comprehensive Cancer Center (UCLA); University of
Wisconsin Carbone Cancer Center (University of Wisconsin) in Madison; VU University
Medical Center (VUmc) in Amsterdam,
Netherlands; and Washington
University and Siteman Cancer Center at Barnes-Jewish
Hospital (Washington University) in
St. Louis.
MRIdian Scientific Session presentations will focus on clinical
outcomes including toxicity, local control, and survival. Other
topics include the use of on-line adaptive therapy, stereotactic
body radiation therapy (SBRT), and margin reduction, as well as
research into diffusion weighted MRI for early assessment of
treatment response. MRIdian Scientific Session presentations will
cover a wide array of clinical indications including pancreatic,
breast, cervical, lung, gastrointestinal, liver, and prostate
cancers.
"We are pleased to have so many leading institutions from around
the world sharing their exciting experience with ViewRay's
MR-guided radiation therapy systems at this year's ASTRO," said
Chris A. Raanes, president and chief
executive officer of ViewRay. "With the only MR-guided radiation
therapy systems on the market today, ViewRay is proud to be
introducing its second generation system, MRIdian Linac, and paving
the way for this important advance in radiation oncology. Now in
its fourth year of patient treatments, MRIdian's value continues to
be reinforced by user feedback and patient outcomes."
Also at this year's ASTRO, ViewRay will host the inaugural
meeting of its Clinical Cooperative Think Tank
(C2T2), a group of MRIdian clinical users and
customers focused on evidence-gathering to support MR-guided
radiation therapy. Recent customers that have been invited to the
C2T2 include Dana-Farber/Brigham and Women's Cancer Center in
Boston; Moffitt Cancer Center in
Tampa, Florida; Institut du Cancer
de Montpellier, and Institut Paoli Calmettes, Marseille in France. The meeting will be hosted by
ViewRay's newly appointed Executive Director for
C2T2, Martin
Fuss, M.D., Ph.D.
Visitors to ViewRay's booth #1317 can observe first-hand
clinical experience with the world's first commercially available
MR-Linac from clinicians at Henry Ford Cancer Institute, as well as
MRIdian presentations from institutions around the world including
SNUH; UCLA; Gemelli ART; VUmc; and
Washington University. These
presentations will take place at various times from Sunday, September 24 through Tuesday, September 26.
ViewRay will also host one of ASTRO's Industry Expert Theater
sessions, titled "Pioneering Clinical Experience with MRIdian Linac
& Improved Clinical Outcomes with On-Table Adaptive RT," which
will take place on Tuesday, September
26 at 12:30 p.m. in Theater 1.
The session will feature presentations by three speakers: Carri
Glide-Hurst, Ph.D. from Henry Ford Cancer Institute will present on
the initial clinical experience with MRIdian Linac; Maria Thomas, M.D., Ph.D. from Washington University will discuss accelerated
treatments of breast cancer with MRIdian; and Frank Lagerwaard,
M.D., Ph.D., from VUmc will present a streamlined process for
online adaptive treatment of pancreatic cancer with MRIdian.
A full list of MRIdian-focused ASTRO Scientific Session
presentations and in-booth talks is available at
http://www.viewray.com/ASTRO_2017.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian integrates MRI
technology, radiation delivery and proprietary software to locate,
target and track the position and shape of soft-tissue tumors
during radiation. ViewRay believes this combination of enhanced
visualization and accuracy will significantly improve outcomes for
patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to the presentations to be
featured at ASTRO. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
These forward-looking statements are made as of the date of this
press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all
of the information set forth herein and should also refer to the
risk factor disclosure set forth in the reports and other documents
ViewRay files with the SEC available at www.sec.gov.
View original
content:http://www.prnewswire.com/news-releases/viewray-mridian-to-be-featured-in-21-presentations-from-seven-leading-centers-at-astro-300523440.html
SOURCE ViewRay, Inc.